Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
better decrease » teer decrease (Expand Search), between decreased (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
better decrease » teer decrease (Expand Search), between decreased (Expand Search)
-
2601
-
2602
-
2603
Verification of PLUS CYCLE<sup>®</sup> signals during presumed sleep periods.
Published 2025Subjects: -
2604
-
2605
-
2606
Combination therapy exhibited apoptosis in Ba/F3 EML4-ALKmutant cell models.
Published 2025Subjects: -
2607
-
2608
The characteristics of patient groups were used to prove the method’s applicability.
Published 2025Subjects: -
2609
-
2610
-
2611
-
2612
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
2613
-
2614
-
2615
-
2616
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
2617
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
2618
-
2619
-
2620
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: